Ignite Creation Date:
2025-12-26 @ 10:17 PM
Ignite Modification Date:
2025-12-26 @ 10:17 PM
Study NCT ID:
NCT00442312
Status:
UNKNOWN
Last Update Posted:
2007-03-01
First Post:
2007-02-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy
Sponsor:
Genovate Biotechnology Co., Ltd.,
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-05
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2006-11
Completion Date Type:
None
First Submit Date:
2007-02-27
First Submit QC Date:
None
Study First Post Date:
2007-03-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2007-02-28
Last Update Post Date:
2007-03-01
Last Update Post Date Type:
ESTIMATED